Steven Leonard Chapman Sells 2,322 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 2,322 shares of Natera stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $240.53, for a total value of $558,510.66. Following the completion of the sale, the chief executive officer directly owned 216,828 shares of the company’s stock, valued at $52,153,638.84. The trade was a 1.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, January 28th, Steven Leonard Chapman sold 3,648 shares of Natera stock. The stock was sold at an average price of $237.66, for a total transaction of $866,983.68.
• On Wednesday, January 21st, Steven Leonard Chapman sold 1,590 shares of Natera stock. The shares were sold at an average price of $235.00, for a total transaction of $373,650.00.
• On Tuesday, January 20th, Steven Leonard Chapman sold 71,932 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $16,885,317.68.
• On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The stock was sold at an average price of $229.08, for a total value of $881,499.84.
• On Monday, December 1st, Steven Leonard Chapman sold 4,400 shares of Natera stock. The stock was sold at an average price of $238.07, for a total transaction of $1,047,508.00.
• On Monday, November 3rd, Steven Leonard Chapman sold 160,703 shares of Natera stock. The shares were sold at an average price of $199.96, for a total transaction of $32,134,171.88.

Natera Stock Down 0.1%

NASDAQ:NTRA opened at $231.14 on Friday. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36. The business’s 50-day simple moving average is $235.91 and its two-hundred day simple moving average is $193.80. The stock has a market cap of $31.97 billion, a PE ratio of -100.93 and a beta of 1.62.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. During the same period in the prior year, the firm posted ($0.26) earnings per share. The firm’s revenue for the quarter was up 34.7% on a year-over-year basis. Sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NTRA has been the topic of several research reports. UBS Group boosted their price target on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Guggenheim boosted their target price on Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research report on Monday, January 5th. BTIG Research boosted their target price on shares of Natera from $230.00 to $260.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Canaccord Genuity Group reaffirmed a “buy” rating on shares of Natera in a research note on Monday, January 12th. Finally, Barclays lifted their price objective on Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.20.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced completion of enrollment in the randomized ACES‑EMB heart‑transplant trial — a clinical milestone for the transplant franchise (Prospera) that de‑risks the program’s pathway to clinical readouts and potential uptake. Article Title
• Positive Sentiment: Wall Street coverage remains largely favorable: multiple firms maintain buy/outperform views and several have raised targets (MarketBeat summary shows consensus around a “Moderate Buy” and an average target near $249). This supports upside expectations if results and growth continue.
• Neutral Sentiment: Natera reported preliminary Q4 revenue (details in the alert). Preliminary figures may influence sentiment when the final quarter report and guidance are released; investors should watch the formal Q4 release for confirmation versus consensus. Preliminary Q4 Revenue
• Neutral Sentiment: Institutional ownership remains extremely high (~99.9%), which tends to stabilize the shareholder base but can also concentrate selling/Buying flows when large holders move. (Source: MarketBeat summary.) Institutional Data
• Negative Sentiment: Multiple insider sales by senior executives: CFO Michael Burkes Brophy sold several tranches (totaling 5,064 shares across Jan. 20–29) and CEO Steven Chapman sold several thousand shares (roughly 5,970 shares across Jan. 27–28). These trades total millions of dollars and may create short‑term selling pressure despite insiders retaining large residual stakes. CFO Form 4 CEO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold smaller tranches. While each reduction is under ~1% of those insiders’ holdings, the cluster of sales amplifies negative signaling to the market. Fesko Form 4 Moshkevich Form 4

Institutional Trading of Natera

A number of institutional investors have recently bought and sold shares of the stock. Rakuten Investment Management Inc. acquired a new position in Natera during the third quarter worth $34,096,000. SWS Partners grew its stake in Natera by 11.8% during the 3rd quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock valued at $7,572,000 after acquiring an additional 4,980 shares in the last quarter. Vontobel Holding Ltd. increased its holdings in shares of Natera by 192.5% in the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock valued at $1,373,000 after purchasing an additional 5,614 shares during the last quarter. Baird Financial Group Inc. increased its stake in shares of Natera by 277.8% in the 2nd quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock worth $4,498,000 after acquiring an additional 19,576 shares during the last quarter. Finally, Orion Porfolio Solutions LLC increased its position in Natera by 68.8% during the second quarter. Orion Porfolio Solutions LLC now owns 12,140 shares of the medical research company’s stock worth $2,051,000 after purchasing an additional 4,946 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.